Fixed-dose combination tablet of repaglinide and metformin is bioequivalent to concomitantly administered individual tablets of repaglinide and metformin: Randomized, single-blind, three-period crossover study in healthy subjects

Clinical Drug Investigation

Volumn 28, Issue 9, 2008, Pages 573-582

  Hoelscher, David ^a   Chu, Pei Ling ^b   Lyness, William ^b  

^a Pharmaceutical Product Development   (United States)

^b NOVO NORDISK INC   (United States)

Author keywords

Antihyperglycaemics, pharmacokinetics; Bioequivalence; Metformin, pharmacokinetics; Repaglinide, pharmacokinetics; Repaglinide metformin, pharmacokinetics; Research and development

Indexed keywords

METFORMIN; METFORMIN PLUS REPAGLINIDE; REPAGLINIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TABLET FORMULATION;

ADOLESCENT; ADULT; AREA UNDER CURVE; CARBAMATES; CROSS-OVER STUDIES; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PIPERIDINES; SAMPLE SIZE; SINGLE-BLIND METHOD; THERAPEUTIC EQUIVALENCY; YOUNG ADULT;

EID: 48349111689     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200828090-00004     Document Type: Article

References (15)

1. Owens DR. Repaglinide: prandial glucose regulator. A new class of oral antidiabetic drugs. Diabet Med 1998; 15 Suppl. 4: S28-36
2. Bailey CJ, Day C. Metformin: its botanical background. Pract Diabetes Int 2004; 21 (3): 115-7
3. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999; 22 (1): 119-24
4. Rudovich NN, Leyck Dieken MG, Rochlitz H, et al. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2004; 112 (7): 395-400
5. Raskin P, Klaff L, McGill J, et al. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26 (7): 2063-8
6. Soegondo S, Subekti I, Luthariana L. The efficacy of repaglinide monotherapy and in combination with metformin in Indonesian type 2 diabetes mellitus patients. Acta Med Indones 2004; 36 (3): 142-7
7. Reboussin DM, Goff Jr DC, Lipkin EW, et al. The combination oral and nutritional treatment of late-onset diabetes mellitus (CONTROL DM) trial results. Diabet Med 2004; 21 (10): 1082-9
8. Shapiro MS, Abrams Z, Lieberman N. Clinical experience with repaglinide in patients with non-insulin-dependent diabetes mellitus. ISR Med Assoc J 2005; 7 (2): 75-7
9. Sturis J, Elm T, Due AL, et al. Combination of repaglinide and metformin results in greater than additive (synergistic) effects on glucose tolerance in obese Zucker (fa/fa) rats. Diabetes Metab 2003; 29 (Hors serie 2): 4S259
10. Moses R. Repaglinide in combination therapy with metformin in type 2 diabetes. Exp Clin Endocrinol Diabetes 1999; 107 Suppl. 4: S136-9
11. Moses R. Repaglinide in combination therapy. Diabetes Nutr Metab 2002; 15 (6 Suppl.): 33-8
12. Moses R. Repaglinide in combination therapy in type 2 diabetes. Diabetes Metab 1999; 25: 26-7
13. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007; 120 (8): 713-9
14. Melikian C, White TJ, Vanderplas A, et al. Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002; 24 (3): 460-7
15. Williams EJ. Experimental designs balanced for the estimation of residual effects of treatment. Aust J Sci Res 1949; 2: 149-68